213 related articles for article (PubMed ID: 33995405)
21. Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs.
Jia Y; Yang Q; Wang Y; Li W; Chen X; Xu T; Tian Z; Feng M; Zhang L; Tang W; Tian N; Zhou L; Song W; Zhao X
Cell Mol Immunol; 2021 Jul; 18(7):1783-1797. PubMed ID: 32099075
[TBL] [Abstract][Full Text] [Related]
22. A novel monoallelic gain of function mutation in p110δ causing atypical activated phosphoinositide 3-kinase δ syndrome (APDS-1).
Lougaris V; Baronio M; Moratto D; Tampella G; Gazzurelli L; Facchetti M; Martire B; Cardinale F; Lanzarotto F; Bondioni MP; Villanacci V; Grimbacher B; Plebani A
Clin Immunol; 2019 Mar; 200():31-34. PubMed ID: 30639166
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Del Pino-Molina L; Torres Canizales JM; Rodríguez-Pena R; López-Granados E
Cytometry B Clin Cytom; 2021 Jul; 100(4):460-466. PubMed ID: 32961022
[TBL] [Abstract][Full Text] [Related]
24. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
[TBL] [Abstract][Full Text] [Related]
25. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
[TBL] [Abstract][Full Text] [Related]
26. Dysregulated actin dynamics in activated PI3Kδ syndrome.
Wallace JG; Zambrano-Rodas P; Córdova-Calderón W; Estrada-Turriate S; Mendoza-Quispe D; Limache Ontiveros Y; Geha RS; Chou J; Platt CD
Clin Immunol; 2020 Jan; 210():108311. PubMed ID: 31760094
[TBL] [Abstract][Full Text] [Related]
27. [Activated phosphoinositide 3-kinase delta syndrome: report of seven cases].
Liu QH; Peng L; Huang H; Deng LJ; Zhong LL
Zhongguo Dang Dai Er Ke Za Zhi; 2024 May; 26(5):499-505. PubMed ID: 38802911
[TBL] [Abstract][Full Text] [Related]
28. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
[TBL] [Abstract][Full Text] [Related]
29. APDS2 and SHORT Syndrome in a Teenager with PIK3R1 Pathogenic Variant.
Ramirez L; Tamayo W; Ale H
J Clin Immunol; 2020 Oct; 40(7):1020-1025. PubMed ID: 32778990
[TBL] [Abstract][Full Text] [Related]
30. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
[TBL] [Abstract][Full Text] [Related]
31. Infections in activated PI3K delta syndrome (APDS).
Brodsky NN; Lucas CL
Curr Opin Immunol; 2021 Oct; 72():146-157. PubMed ID: 34052541
[TBL] [Abstract][Full Text] [Related]
32. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review.
Schworer SA; Francis OL; Johnson SM; Smith BD; Gold SH; Smitherman AB; Wu EY
J Pediatr Hematol Oncol; 2021 Nov; 43(8):281-287. PubMed ID: 34054047
[TBL] [Abstract][Full Text] [Related]
34. Paediatric MAS/HLH caused by a novel monoallelic activating mutation in p110δ.
Lougaris V; Baronio M; Castagna A; Tessarin G; Rossi S; Gazzurelli L; Benvenuto A; Moratto D; Chiarini M; Cattalini M; Facchetti M; Palumbo L; Giliani S; Girelli MF; Badolato R; Bondioni MP; Facchetti F; Meini A; Plebani A
Clin Immunol; 2020 Oct; 219():108543. PubMed ID: 32681977
[TBL] [Abstract][Full Text] [Related]
35. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
Front Immunol; 2018; 9():568. PubMed ID: 29675019
[TBL] [Abstract][Full Text] [Related]
36. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
[TBL] [Abstract][Full Text] [Related]
37. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
[TBL] [Abstract][Full Text] [Related]
38. Activated Phosphoinositide 3 Kinase Delta Syndrome (APDS): A Primary Immunodeficiency Mimicking Lymphoma.
Baleydier F; Ranza E; Schäppi M; Rougemont AL; Merlini L; Ansari M; Blanchard-Rohner G
J Pediatr Hematol Oncol; 2019 Nov; 41(8):e521-e524. PubMed ID: 30334905
[TBL] [Abstract][Full Text] [Related]
39. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
Liu H; Tang XL; Liu JR; Li HM; Zhao SY
Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
[TBL] [Abstract][Full Text] [Related]
40. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
